+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Hereditary Angioedema Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • ID: 4997607
  • Report
  • April 2021
  • Region: Global
  • 110 pages
  • Mordor Intelligence


  • Cipla Inc.
  • CSL Behring
  • Ionis Pharmaceuticals
  • Pharming Healthcare, Inc.
  • Sanofi
  • MORE
The hereditary angioedema therapeutics market is expected to register a CAGR of 8.5% during the forecast period.

Owing to the current pandemic situation, there is a continuous urge to develop a treatment and vaccine, pharmaceutical companies have dedicated their R&D resources completely to support the COVID-19 vaccine development. Research and development activities for rare diseases including hereditary angioedema have been outlined for the time being in R&D laboratories. However, some companies are focusing their R&D resources to understand the effect of COVID-19 in patient with rare diseases and carrying out Esoteric Testing to determine novel therapies for COVID-19 patients.

The major factor attributing to the growth of the market is the increasing awareness of the treatment for rare diseases such as hereditary angioedema (HAE). As per the National Organization for Rare Disorders (NORD), the condition is believed to affect about 1 in 50,000 people to 1 in 150,000 individuals is affected by this disorder worldwide. Angioedema attacks usually occur in the form of sudden regularly painful swelling in numerous parts of the body, involving the abdomen, extremities, throat, and face. Many organizations are spreading awareness about the diseases and their treatment, like the US Hereditary Angioedema Association, which is a non-profit organization dedicated to offering HAE patients access to the latest treatment options and dependable, personal support to address symptoms and the challenges associated with the condition. As per an article published on the National Library of Medicine in October 2020, a study was conducted in 2020 to evaluate the current HAE management and the new treatment options on physician practice patterns over time. The study suggested that as per the survey conducted in the United States physicians reported improvements in the HAE management in recent years. Owing to the current therapeutic advances the reported cases of HAE have improved and reduced concern of adverse treatment effects, and high levels of patient satisfaction have been observed.

Furthermore, increasing funding for rare genetic diseases and orphan drugs by the government and private companies is also enhancing the interest of the pharmaceutical companies to develop drugs for hereditary angioedema and is fueling the market growth. For instance, in November 2020 Takeda Pharmaceutical entered into an agreement for public funding in Canada of Takhzyro (lanadelumab), its treatment for eligible hereditary angioedema (HAE) patients. Also, the National Institutes of Health (NIH) also supports research to improve the health of people with rare diseases. Many of the 27 Institutes and Centers receives NIH fund for medical research of rare diseases. However, misdiagnosis of the condition, as common allergies, appendicitis, and Irritable Bowel Syndrome, has steered to an interruption inefficient treatment, which has had a considerable negative impact on the growth of the global hereditary angioedema treatment market.

Key Market Trends

Kallikrein Inhibitors Segment is the Fastest Growing in the Hereditary Angioedema Therapeutics Market

Kallikrein Inhibitors are expected to be the fastest-growing segment over the forecast period. Currently, various kallikrein inhibitors are being evaluated owing to their potential to prevent edematous HAE attacks. This comparatively emerging class of drug therapy has several potential molecules in the pipelines, commercialization of which is expected to fuel the market growth. For instance, BioCryst is currently developing a novel treatment to treat and prevent angioedema attacks in patients with hereditary angioedema (HAE), and is evaluating the molecule APeX-1, an oral, once-daily, selective inhibitor of plasma kallikrein. Also, the pharmaceutical companies are rapidly seeking approval in this class of drugs as there is comparatively less competition in this market space. For instance, in August 2020 the United States Food and Drug Administration approved Takhzyro (lanadelumab), the first monoclonal antibody that targets Kallikrein and is indicated for the treatment of patients 12 years and older with types I and II HAE.

Owing to all these developments the Kallikerin inhibitors segment is expected to augment market growth. In addition, increasing research and development and funding for orphan drug development and for rare genetic disorders is also expected to further fuel the market growth. For instance, the Indian Ministry of Health and Family Welfare developed a National Policy for treatment of rare diseases in India to progressively expand India’s capabilities to treat rare diseases. The ministry released funding of an initial amount of INR 100 crore towards the treatment of rare genetic diseases. Hence, the increased funding for research and development for new drugs is propelling the segment growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall hereditary angioedema market during the forecast period. The market growth is due to the factors such as the presence of key players, Increasing awareness programs and research organizations regarding the treatment of the condition, and established healthcare infrastructure. Moreover, the increasing government initiatives, rising research partnerships, and the presence of a robust pipeline are the major growth drivers of the market. For instance, Ionis Pharmaceuticals, a biotechnology company based in California currently has IONIS-PKK-LRx is a ligand-conjugated (LICA) investigational antisense medicine in its pipeline. The company is evaluating the drug molecule to reduce the production of prekallikrein, or PKK, to treat patients with hereditary angioedema. Also, there is a presence of a large number of government and non-government-funded research institutions in this region. For instance, the National Center for Advancing Translational Sciences (NCATS) is completely focused on esoteric testing for the cure and treatments for rare diseases. NCATS is aimed at getting collaborative projects to study common themes and causes of related diseases to speed the development of treatments. Hence, owing to all the aforementioned factors the market is anticipated to have lucrative growth in the future.

Competitive Landscape

The hereditary angioedema therapeutics market is highly consolidated in terms of competition and consists of limited major players. Some of the companies which are currently dominating the market are CSL Behring, Takeda Pharmaceutical Company Limited, Takeda Pharmaceutical Company, Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Attune Pharmaceuticals, Inc., Ionis Pharmaceuticals, KalVista Pharmaceuticals, Inc, Adverum Biotechnologies, Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Cipla Inc.
  • CSL Behring
  • Ionis Pharmaceuticals
  • Pharming Healthcare, Inc.
  • Sanofi
  • MORE
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Awareness Levels for Hereditary Angioedema
4.2.2 Increasing Research and Development and Funding for Orphan Drug Development
4.3 Market Restraints
4.3.1 Misdiagnosis of Hereditary Angioedema
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Class
5.1.1 C1 Esterase Inhibitor
5.1.2 Selective Bradykinin B2 Receptor Antagonist
5.1.3 Kallikrein Inhibitor
5.1.4 Others
5.2 By Route of Administration
5.2.1 Intravenous
5.2.2 Subcutaneous Injection
5.2.3 Oral
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 CSL Behring
6.1.2 Takeda Pharmaceutical Company Limited
6.1.3 Sanofi
6.1.4 Pharming Healthcare, Inc.
6.1.5 BioCryst Pharmaceuticals, Inc.
6.1.6 Attune Pharmaceuticals, Inc.
6.1.7 Ionis Pharmaceuticals
6.1.8 KalVista Pharmaceuticals, Inc
6.1.9 Adverum Biotechnologies, Inc
6.1.10 Cipla Inc.
6.1.11 Arrowhead Pharmaceuticals Inc

Note: Product cover images may vary from those shown
  • CSL Behring
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Pharming Healthcare, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Attune Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals
  • KalVista Pharmaceuticals, Inc
  • Adverum Biotechnologies, Inc
  • Cipla Inc.
  • Arrowhead Pharmaceuticals Inc
Note: Product cover images may vary from those shown